Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in diffuse large B cell lymphoma patients

Patients to be included must be before initiation of second-line treatment in or conform OMB 110928 study, meeting the following criteria (conform the inclusion criteria of OMB 110928 study protocol):;Patients have refractory or relapsed (see protocol for definition) CD20 positive DLBCL during or after first line treatment with rituximab combined with anthracycline-based chemotherapy, confirmed by biopsy after first line treatment.;Age 18 years or older. Baseline 18F-FDG PET scan with positive lesions, compatible with CT defined anatomical tumor sites. CT-scan showing at least one or more clearly demarcated lesions with a largest diameter * 1.5 cm or 1 clearly demarcated lesion with a largest diameter * 2.0 cm (not previously irradiated). ECOG performance status 0,1 or 2. Patients must be eligible for high dose chemotherapy and autologous stem cell transplantation. Resolution of toxicities from first-line therapy to grade * 1. Patients must be able to adhere to the study appointments and other protocol requirements. Patients must be capable of giving written informed consent and the consent must have been obtained prior to the study related procedures.

Patients are excluded if they meet the following criteria (conform the exclusion criteria of OMB 110928 study protocol):;- any previous therapy for DLBCL, with the exception of first-line treatment with rituximab in combination with anthracycline-based chemotherapy, or radiotherapy as part of the first-line treatment plan or to a limited field at a aximum dose of *10Gy to control life-threatening symptoms.;- received any of the following treatments within 4 weeks prior to start of trial therapy (unless otherwise stated): anti-cancer therapy, radiotherapy (unless limited field at a maximum dose of * 10Gy to control life-threatening symptoms), treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrolment (whichever is longer) or currently participating in any other interventional clinical study, glucocorticoid use, unless given in doses *100 mg/day hydrocortisone (or equivalent dose of other glucocorticoids) for < 7 days for exacerbations other than lymphoma (e.g. asthma). ;- Significant cerebrovascular disease. ;- Chronic or active infections with systemic treatment with antibiotics, antifungal or antiviral medication. ;- Other malignancy. ;- Prior treatment with monoclonal antibodies, with the exception of rituximab, within 3 months prior to start of the study.;- Pregnancy or lactation;- Women of childbearing potential or male subjects, unable or unwilling to adhere to the adequate contraception conform study protocol.